I have watched a lot of growth stories over the years where the forecast kept getting revised down after the stock was already priced for the high end. Eli Lilly is the rare case of the opposite. Every year the estimates for how large the obesity drug market becomes get revised up, and Lilly is one of two companies positioned to take most of it. That does not make the stock cheap. It does change how I think about paying up for it.
The Number That Keeps Moving
A few years ago, a common Wall Street estimate for the global obesity drug market by 2030 was somewhere around fifty billion dollars a year. Then it was one hundred billion. Now the midpoint of published forecasts sits closer to one hundred and thirty billion, and the more aggressive shops are at one hundred and fifty. The reason the estimate keeps climbing is that every new data point on these drugs, cardiovascular benefit, sleep apnea, kidney outcomes, has expanded the population that insurers and doctors will treat. What started as a weight-loss product is turning into a chronic metabolic therapy that a large share of the developed world could be on for decades.
Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has been taking share against Novo Nordisk’s competing products, and the clinical readouts have generally favored Lilly on the magnitude of weight loss. The Eli Lilly analyst page is where I watch consensus targets and estimate revisions move in the weeks after each of those readouts, which tells me more than the price reaction on the day. That is the current engine. The forecast question is about what comes next.
The Pipeline Is the Real Bet
Two drugs matter most. Orforglipron is an oral GLP-1 pill rather than an injection. If the efficacy and safety hold up in the full Phase 3 program and it reaches the market, a pill is far easier to manufacture at scale and to distribute globally than a weekly shot, which addresses the single biggest bottleneck this category has faced. Retatrutide is a triple-hormone drug that has produced weight loss in trials approaching what people used to associate only with bariatric surgery. If both work, Lilly is not just a leader in this market, it sets the ceiling for it.
Neither is guaranteed. Oral drugs can carry tolerability issues that injectables do not. More potent drugs raise questions about muscle loss and long-term safety that regulators will scrutinize. And Novo is not standing still, with its own oral and combination candidates moving through trials. But the direction of travel has favored Lilly for three straight years, and that is not nothing.
Capacity, Which Is Where This Gets Concrete
The clearest evidence that Lilly believes its own forecast is the manufacturing spend. The company has committed tens of billions of dollars to new plants in the United States and Europe, building capacity years ahead of the demand it expects. That is capital at risk if the market turns out smaller than projected, and it is the reason near-term margins are not expanding as fast as revenue. It also means that when a supply-constrained product finally has enough supply, the growth can step up rather than plateau. The Lilly quote page shows what the run of good news has done to the valuation, which is the other half of the decision.
| Driver | What has to happen | Risk if it does not |
|---|---|---|
| Tirzepatide share | Holds or gains against Novo | Pricing pressure as the market matures |
| Orforglipron (oral) | Phase 3 efficacy and tolerability hold, launches | Loses the scale and access advantage of a pill |
| Retatrutide | Best-in-class weight loss confirmed, safety clean | Ceiling on the franchise set by someone else |
| Manufacturing | New capacity comes online on schedule | Stranded capital, margin drag without the revenue |
How I Hold It
Lilly is expensive on every trailing metric, and it has still been one of the better large-cap holdings of the past three years because the earnings caught up to the multiple and then kept going. The forward multiple has actually come down from its peak even as the stock rose, because estimates rose faster. That is the pattern you want in a growth name. My worry is not the business, it is position sizing, and the way I think about that is in a piece on the system I use to pick stocks. The quant rating tool captures the tension in one place, with Growth and Valuation pulling hard against each other. This is a name that can drop thirty percent on one disappointing trial readout, and the pipeline has several of those due over the next eighteen months. So I own it at a size I can sit through, I have not added at the highs, and I treat a pipeline-driven selloff as the entry, not the exit.
Gavin Thorne writes on equity strategy and company-level research. This article reflects his personal research process and is intended for informational purposes only. It does not constitute investment advice.